More than 10 years into this bull market, Buy and Outperform analyst ratings generally come with implied upside potential of 8% to 10%. However, the author of today’s article notes that “One area of the market that can see much greater upside opportunities, which also implies a greater risk, is the biotech and emerging pharmaceutical stocks” – and he proceeds to highlight 20 biotech and pharma stocks that have seen analyst calls since January 1st that suggest much larger upside potential. For more, CLICK HERE.
20 Biotech And Pharma Stocks Offering More-Than-Your-Average Upside Potential
- by Bob Mitchell
Tags:Analyst RatingsBiotech InvestmentsBiotech StocksBull MarketBuy and PerformHealthcare BusinessInvestMarket AnalystPharma StocksPharmaceutical InvestmentsStock MarketUpside Potential